- Home
- VIR vs CHY Comparison
VIR vs CHY Comparison
Compare VIR & CHY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIR
- CHY
- Stock Information
- Founded
- VIR 2016
- CHY 2003
- Country
- VIR United States
- CHY United States
- Employees
- VIR N/A
- CHY N/A
- Industry
- VIR Biotechnology: Pharmaceutical Preparations
- CHY Investment Managers
- Sector
- VIR Health Care
- CHY Finance
- Exchange
- VIR Nasdaq
- CHY Nasdaq
- Market Cap
- VIR 844.9M
- CHY 792.1M
- IPO Year
- VIR 2019
- CHY N/A
- Fundamental
- Price
- VIR $5.23
- CHY $10.52
- Analyst Decision
- VIR Strong Buy
- CHY
- Analyst Count
- VIR 7
- CHY 0
- Target Price
- VIR $32.86
- CHY N/A
- AVG Volume (30 Days)
- VIR 1.4M
- CHY 128.3K
- Earning Date
- VIR 07-31-2025
- CHY 01-01-0001
- Dividend Yield
- VIR N/A
- CHY 10.11%
- EPS Growth
- VIR N/A
- CHY N/A
- EPS
- VIR N/A
- CHY N/A
- Revenue
- VIR $20,861,000.00
- CHY N/A
- Revenue This Year
- VIR N/A
- CHY N/A
- Revenue Next Year
- VIR N/A
- CHY N/A
- P/E Ratio
- VIR N/A
- CHY N/A
- Revenue Growth
- VIR N/A
- CHY N/A
- 52 Week Low
- VIR $4.32
- CHY $9.97
- 52 Week High
- VIR $14.45
- CHY $12.16
- Technical
- Relative Strength Index (RSI)
- VIR 50.23
- CHY 53.00
- Support Level
- VIR $5.02
- CHY $10.46
- Resistance Level
- VIR $5.34
- CHY $10.79
- Average True Range (ATR)
- VIR 0.25
- CHY 0.10
- MACD
- VIR 0.03
- CHY -0.02
- Stochastic Oscillator
- VIR 47.53
- CHY 42.55
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
About CHY Calamos Convertible and High Income Fund
Calamos Convertible & High Income Fund is a diversified, closed-end management investment company. Its objective is to provide total return through a combination of capital appreciation and current income. The firm invests in a diversified portfolio of convertible securities and high-yield securities.